Genetic Testing Market Analysis, Size, Share & Growth Forecast 2026–2034

Whole Genome Sequencing Below USD 200 per Clinical Genome Has Enabled NHS England and US Newborn Sequencing Programmes to Identify Rare Inherited Conditions That Standard Metabolic Newborn Screening Cannot Detect.The DTC genetic testing business model offering SNP-based microarray analysis of 600,000 to 2 million genetic variants for ancestry composition, relative matching, and FDA-cleared health predisposition reports has established consumer genomics as a mainstream wellness and curiosity product market at price points below USD 100 per test. The FDA's LDT laboratory developed test clearance of 23andMe for BRCA1/2 variant testing, pharmacogenomics drug response variants, and polygenic risk scores for common disease has created the regulatory pathway that distinguishes the FDA-cleared health genetic report from the ancestry-only reports that do not require FDA clearance. The genetic privacy concerns raised by DTC genetic testing have driven GDPR enforcement actions against genetic data controllers in Europe and state-level genetic privacy legislation in the US that restricts the secondary use of genetic data for insurance and employment decisions.

Pre-Emptive Pharmacogenomic Panel Results in EHR With Prescriber CDS Alerts at Drug Ordering Are Enabling Proactive Genotype-Guided Prescribing That Prevents Adverse Drug Reactions in the 25 Percent of Drugs With Actionable Pharmacogenomic Profiles.GeneDx, Blueprint Genetics, and Invitae provide the clinical exome and genome sequencing services that paediatric geneticists and neurologists order for the diagnostic odyssey patients with suspected rare genetic disease who have not achieved diagnosis through targeted gene panel testing. The American College of Medical Genetics and Genomics guidelines for the reporting of secondary findings in clinical exome and genome sequencing defining the 73 ACMG actionable gene variants that laboratories must offer to report provide the clinical framework that has standardised the secondary finding reporting practice across clinical genome sequencing laboratories. The newborn genome sequencing programme pilots in the US, UK, and several European countries evaluating the clinical utility of genome sequencing at birth for early identification of treatable childhood-onset conditions represent the highest-impact application of clinical genomics that could transform newborn screening from the 30-40 conditions detectable by current biochemical panels to the thousands of genetic conditions detectable by genome sequencing.

Comprehensive Tumour Genomic Profiling Identifying Actionable Mutations in 300 to 500 Cancer Genes Is Matching Patients With the Targeted Therapies and Clinical Trials That Their Molecular Profile Supports.OneOme's RightMed pharmacogenomics test, Myriad Genetics' GeneSight psychiatric pharmacogenomics panel, and Mayo Clinic's pharmacogenomics programme provide the multi-drug multi-gene pharmacogenomics testing that supports individualised medication selection and dosing based on each patient's genetic variants affecting drug metabolism, transport, and receptor binding. The CYP2D6 and CYP2C19 genetic variants affecting metabolism of antidepressants, antipsychotics, and antiplatelet drugs have the strongest clinical evidence base for pharmacogenomics prescribing guidance, and the clinical decision support integration of pharmacogenomics results in electronic health records from Epic and Cerner provides the point-of-care prescribing alerts that translate genetic results into clinical action. The pharmacogenomics return on investment demonstrated through studies showing reduced adverse drug reactions and hospitalisation costs when pharmacogenomics-guided prescribing is implemented has supported the health system investment in population-level pharmacogenomics programmes that pre-emptively genotype patients before they require affected medications.

For related market intelligence, see the Next Generation Sequencing Market.